HTG Investment Advisors’s Pfizer PFE Stock Holding History

HTG Investment Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,290	Closed	-$220K	–	52
2022 Q4	$220K	Buy	+4,290	New	+$206K	0.22%	48

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HTG Investment Advisors's PFE Position: Q1 2023 in Review

HTG Investment Advisors sold out of Pfizer (PFE) in Q1 2023, closing a stake of 4,290 shares — an estimated $220K sold.

HTG Investment Advisors first reported a position in PFE in Q4 2022 and held it in 1 quarter. The position peaked at $220K in Q4 2022. 3,102 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

HTG Investment Advisors reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
HTG Investment Advisors sold 4,290 Pfizer shares in Q1 2023, an estimated $220K.
HTG Investment Advisors first reported a position in Pfizer in Q4 2022 and held it in 1 quarter.
HTG Investment Advisors's Pfizer position peaked at $220K in Q4 2022.
3,102 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on HTG Investment Advisors's 13F filing for Q1 2023, filed 13 Apr 2023.